AI-generated summary
The authors describe a protocol for a planned randomized, double-blind trial of photobiomodulation to reduce pain during copper T 380 intrauterine device placement in Brazil. Seventy-two women are to be randomly assigned to active or sham treatment, with pain measured on a visual analog scale. The abstract reports no findings, since the trial is described as a protocol only.
- Participants
- 72
- Who or what was studied
- Women undergoing placement of the copper T 380 intrauterine device in Brazil, planned as 72 randomized participants.
- Limits stated in the abstract
- The abstract describes a study protocol only, so no results or effectiveness data are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Unplanned pregnancy remains a critical public health issue in Brazil that affects up to 65% of women in some regions and increases the incidence of both unsafe abortions and maternal mortality. Although the copper intrauterine device (IUD) is a highly effective, long-acting contraceptive method, its rate of use remains low in Brazil (only 4.4% of women of reproductive age). One of the primary barriers is the pain experienced during placement of the device, which discourages adherence. Although multiple social and cultural determinants influence IUD uptake, insertion-related pain constitutes a modifiable, procedure-specific factor that may directly affect both pain perception and anticipatory discomfort. Conventional pain management strategies, such as anti-inflammatories and local anesthetics, have produced inconsistent results. Photobiomodulation (PBM) is a non-invasive therapy with anti-inflammatory and analgesic properties that has shown promise in managing pelvic pain in contexts such as labor.
Methods And Analysis
The proposed randomized, double-blind clinical trial will investigate the effectiveness of PBM at reducing pain during the placement of the copper T 380 IUD. Seventy-two women will be randomly allocated to either an active PBM group (n = 36) or sham PBM control group (n = 36). In all participants, the standard IUD placement protocol will follow the guidelines of the Brazilian Ministry of Health. Pain will be assessed using the Visual Analog Scale (VAS) at multiple time points: during each step of insertion (Pozzi clamp, hysterometry, IUD placement) as well as 5 min, 15 min, 24 hours, and 48 hours post-procedure. The secondary outcomes will be analgesic use, anxiety levels (GAD-7), quality of life (WHOQOL-100), satisfaction with the procedure, and adverse effects. Ethics and dissemination. This clinical trial received approval from the Research Ethics Committee of the Mandaqui Hospital Complex (process: 7.367.867) and was registered in ClinicalTrials.gov (NCT06984796). Statistical analyses will be conducted using SPSS v24.0, with a significance level of 5%. Either parametric or nonparametric tests will be applied, depending on the data distribution. Kaplan-Meier curves will be used to assess time to pain resolution. The results will be disseminated through peer-reviewed publications.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Visual analogue scale, Control group, Anxiety, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.